

## Complete Summary

---

### GUIDELINE TITLE

Infection control during GI endoscopy.

### BIBLIOGRAPHIC SOURCE(S)

ASGE Standards of Practice Committee, Banerjee S, Shen B, Nelson DB, Lichtenstein DR, Baron TH, Anderson MA, Dominitz JA, Gan SI, Harrison ME, Ikenberry SO, Jagannath SB, Fanelli RD, Lee K, van Guilder T, Stewart LE. Infection control during GI endoscopy. Gastrointest Endosc 2008 May;67(6):781-90. [109 references] [PubMed](#)

### GUIDELINE STATUS

This is the current release of the guideline.

## COMPLETE SUMMARY CONTENT

SCOPE  
 METHODOLOGY - including Rating Scheme and Cost Analysis  
 RECOMMENDATIONS  
 EVIDENCE SUPPORTING THE RECOMMENDATIONS  
 BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
 QUALIFYING STATEMENTS  
 IMPLEMENTATION OF THE GUIDELINE  
 INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
 CATEGORIES  
 IDENTIFYING INFORMATION AND AVAILABILITY  
 DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Endoscopy-related infections

### GUIDELINE CATEGORY

Management  
 Prevention  
 Treatment

### CLINICAL SPECIALTY

Gastroenterology  
Infectious Diseases  
Internal Medicine

## **INTENDED USERS**

Allied Health Personnel  
Nurses  
Physicians

## **GUIDELINE OBJECTIVE(S)**

- To provide information that may assist endoscopists in providing care to patients
- To disseminate information and promote understanding, which leads to the prevention of infection as a result of a gastrointestinal endoscopy

## **TARGET POPULATION**

Patients undergoing an endoscopic examination

## **INTERVENTIONS AND PRACTICES CONSIDERED**

1. Reprocessing of endoscopies
  - Manual cleaning
  - High-level disinfection (HLD)
  - Sterilization
  - Proper rinsing, drying and storage
2. Antibiotic prophylaxis for gastrointestinal (GI) endoscopic procedures
3. General infection control procedures (e.g., single use of drug vials and use of gloves by health care workers)
4. Use of precautions to avoid infection transmission
  - Standard precautions
  - Precautions at the institutional level
  - Precautions in the endoscopy suite
  - Use of personal protective equipment
5. Postexposure prophylaxis

## **MAJOR OUTCOMES CONSIDERED**

- Incidence of infections (patient to patient; by endoscopy, endogenous) after endoscopic procedures
- Effectiveness in preventing infections as a result of a gastrointestinal (GI) endoscopy

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Hand-searches of Published Literature (Primary Sources)  
Hand-searches of Published Literature (Secondary Sources)  
Searches of Electronic Databases

#### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

A search of the medical literature was performed by using PubMed, supplemented by accessing the "related articles" feature of PubMed. Additional references were obtained from the bibliographies of the identified articles and from recommendations of expert consultants. When little or no data exist from well-designed prospective trials, emphasis is given to results from large series and reports from recognized experts.

#### **NUMBER OF SOURCE DOCUMENTS**

Not stated

#### **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Weighting According to a Rating Scheme (Scheme Given)

#### **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

See "Rating Scheme for the Strength of the Recommendations"

#### **METHODS USED TO ANALYZE THE EVIDENCE**

Systematic Review with Evidence Tables

#### **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not stated

#### **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Expert Consensus

#### **DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Guidelines for appropriate use of endoscopy are based on critical review of the available data and expert consensus.

#### **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

| <b>Grade of Recommendation</b> | <b>Clarity of Benefit</b> | <b>Methodologic Strength Supporting Evidence</b>   | <b>Implications</b>   |
|--------------------------------|---------------------------|--|---|
| 1A                             | Clear                     | Randomized trials without important limitations  | Strong recommendation; can be applied to most clinical settings   |
| 1B                             | Clear                     | Randomized trials with important limitations (inconsistent results, nonfatal methodologic flaws) | Strong recommendation; likely to apply to most practice settings  |
| 1C+                            | Clear                     | Overwhelming evidence from observational studies   | Strong recommendation; can apply to most practice settings in most situations   |
| 1C                             | Clear                     | Observational studies  | Intermediate-strength recommendation; may change when stronger evidence is available                                    |
| 2A                             | Unclear                   | Randomized trials without important limitations  | Intermediate-strength recommendation; best action may differ depending on circumstances or patients' or societal values |
| 2B                             | Unclear                   | Randomized trials with important limitations (inconsistent results, nonfatal methodologic flaws) | Weak recommendation; alternative approaches may be better under some circumstances                                      |

| <b>Grade of Recommendation</b> | <b>Clarity of Benefit</b> | <b>Methodologic Strength Supporting Evidence</b> | <b>Implications</b>   |
|--------------------------------|---------------------------|--|---|
| 2C                             | Unclear                   | Observational studies                            | Very weak recommendation; alternative approaches likely to be better under some circumstances |
| 3                              | Unclear                   | Expert opinion only                              | Weak recommendation; likely to change as data become available                                |

\*Adapted from Guyatt G, Sinclair J, Cook D, et al. Moving from evidence to action. Grading recommendations: a qualitative approach. In: Guyatt G, Rennie D, editors. Users' guides to the medical literature. Chicago: AMA Press; 2002. p. 599-608.

## **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

## **METHOD OF GUIDELINE VALIDATION**

External Peer Review  
Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

This document was reviewed and approved by the Governing Board of the American Society for Gastrointestinal Endoscopy. This document was reviewed and endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Guidelines Committee and Board of Governors.

## **RECOMMENDATIONS**

### **MAJOR RECOMMENDATIONS**

Definitions for the grades of recommendation (1A to 3) are provided at the end of the "Major Recommendations."

### **Reprocessing of Endoscopes**

#### **Definitions**

*Cleaning:* This is defined as the physical removal of organic material and/or soil, usually by using water with detergents. This process is designed to remove microorganisms rather than to kill them.

*Disinfection:* Disinfection accomplishes the killing of most microorganisms and is commonly performed by using liquid chemical germicides (LCG). Three levels of disinfection are achievable: high, intermediate, and low, depending on the amount and kind of microbial killing involved. High level disinfection (HLD) destroys vegetative microorganisms, mycobacteria, fungi, small or nonlipid viruses, medium or lipid viruses, but not necessarily large numbers of bacterial spores. Chemical germicides registered as "sterilants" may be used for sterilization or for HLD, depending on such factors as dilution, contact time, and frequency of reuse. The specifics of such factors may vary with each product and are included on approved labeling.

*Sterilization:* Sterilization is the act of killing all microbial life, including the elimination of bacterial spores. It is most commonly achieved with heat or ethylene oxide gas. The Spaulding classification system allows categorization of medical devices based on the risk of infection involved with use. The categories of medical devices and their associated level of disinfection are as follows:

- Critical use items: Items that enter sterile tissue or vascular spaces and hence carry significant risk for infection if contaminated. These items include needles, surgical instruments, biopsy forceps, and urinary catheters. Processing for reuse of these items requires sterilization. In some instances, gastrointestinal (GI) endoscopes are sterilized when intended for use in sterile environments.
- Semicritical use items: Items that come in contact with mucous membranes and do not ordinarily penetrate sterile tissue. These include thermometers, endoscopes, and anesthesia equipment. Processing for reuse of these items requires at least HLD.
- Noncritical items: Items that do not ordinarily touch the patient or touch only intact skin, such as stethoscopes or patient carts. These items may be cleaned by low-level disinfection.

### **Summary**

- Transmission of infection as a result of GI endoscopes is extremely rare, and recently reported cases are invariably attributable to lapses in currently accepted endoscope reprocessing protocols or to defective equipment. **(Level 1C+)**
- Endoscopes should undergo HLD as recommended by governmental agencies and all pertinent professional organizations for the reprocessing of GI endoscopes. **(Level 1C+)**
- Extensive training of staff involved in endoscopic reprocessing is mandatory for quality assurance and for effective infection control. **(Level 1C)**
- General infection control principles should be adhered to at the endoscopy unit. **(Level 1C+)**
- Transmission of infection from patients to endoscopy personnel can be avoided by application of standard precautions. **(Level 1C+)**

### **Definitions:**

| <b>Grade of Recommendation</b> | <b>Clarity of Benefit</b> | <b>Methodologic Strength Supporting Evidence</b>   | <b>Implications</b>   |
|--------------------------------|---------------------------|--|---|
| 1A                             | Clear                     | Randomized trials without important limitations  | Strong recommendation; can be applied to most clinical settings   |
| 1B                             | Clear                     | Randomized trials with important limitations (inconsistent results, nonfatal methodologic flaws) | Strong recommendation; likely to apply to most practice settings  |
| 1C+                            | Clear                     | Overwhelming evidence from observational studies   | Strong recommendation; can apply to most practice settings in most situations   |
| 1C                             | Clear                     | Observational studies  | Intermediate-strength recommendation; may change when stronger evidence is available                                    |
| 2A                             | Unclear                   | Randomized trials without important limitations  | Intermediate-strength recommendation; best action may differ depending on circumstances or patients' or societal values |
| 2B                             | Unclear                   | Randomized trials with important limitations (inconsistent results, nonfatal methodologic flaws) | Weak recommendation; alternative approaches may be better under some circumstances                                      |

| <b>Grade of Recommendation</b> | <b>Clarity of Benefit</b> | <b>Methodologic Strength Supporting Evidence</b> | <b>Implications</b>   |
|--------------------------------|---------------------------|--|---|
| 2C                             | Unclear                   | Observational studies                            | Very weak recommendation; alternative approaches likely to be better under some circumstances |
| 3                              | Unclear                   | Expert opinion only                              | Weak recommendation; likely to change as data become available                                |

\*Adapted from Guyatt G, Sinclair J, Cook D, et al. Moving from evidence to action. Grading recommendations: a qualitative approach. In: Guyatt G, Rennie D, editors. Users' guides to the medical literature. Chicago: AMA Press; 2002. p. 599-608.

## **CLINICAL ALGORITHM(S)**

None provided

## **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

## **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

### **POTENTIAL BENEFITS**

Appropriate infection control during gastrointestinal (GI) endoscopy

### **POTENTIAL HARMS**

The efficacy of manual cleaning and high-level disinfection (HLD) is personnel dependent. Reprocessing failure incidents typically arise as a result of human error, or because of equipment automatic endoscope reprocessor (AER) or product (HLD) failure.

## **QUALIFYING STATEMENTS**

### **QUALIFYING STATEMENTS**



- Further controlled clinical studies may be needed to clarify aspects of this guideline. This guideline may be revised as necessary to account for changes in technology, new data, or other aspects of clinical practice. This guideline is intended to be an educational device to provide information that may assist endoscopists in providing care to patients.
- This guideline is not a rule and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment. Clinical decisions in any particular case involve a complex analysis of the patient's condition and available courses of action. Therefore, clinical considerations may lead an endoscopist to take a course of action that varies from these guidelines.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better  
Staying Healthy

### IOM DOMAIN

Effectiveness  
Safety

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

ASGE Standards of Practice Committee, Banerjee S, Shen B, Nelson DB, Lichtenstein DR, Baron TH, Anderson MA, Dominitz JA, Gan SI, Harrison ME, Ikenberry SO, Jagannath SB, Fanelli RD, Lee K, van Guilder T, Stewart LE. Infection control during GI endoscopy. *Gastrointest Endosc* 2008 May;67(6):781-90. [109 references] [PubMed](#)

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2008 May

**GUIDELINE DEVELOPER(S)**

American Society for Gastrointestinal Endoscopy - Medical Specialty Society

**SOURCE(S) OF FUNDING**

American Society for Gastrointestinal Endoscopy

**GUIDELINE COMMITTEE**

Standards of Practice Committee

**COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

*Committee Members:* Subhas Banerjee, MD; Bo Shen, MD; Douglas B. Nelson, MD; David R. Lichtenstein, MD; Todd H. Baron, MD, (*Chair*); Michelle A. Anderson, MD; Jason A. Dominitz, MD, MHS; S. Ian Gan, MD, FRCPC; M. Edwyn Harrison, MD; Steven O. Ikenberry, MD; Sanjay B. Jagannath, MD; Robert D. Fanelli, MD, SAGES Representative; Ken Lee, MD, NASPGHAN Representative; Trina van Guilder, RN, SGNA Representative; Leslie E. Stewart, RN, SGNA Representative

**FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Not stated

**GUIDELINE STATUS**

This is the current release of the guideline.

**GUIDELINE AVAILABILITY**

Electronic copies: Available from the [American Society for Gastrointestinal Endoscopy Web site](#).

Print copies: Available from the American Society for Gastrointestinal Endoscopy, 1520 Kensington Road, Suite 202, Oak Brook, IL 60523

**AVAILABILITY OF COMPANION DOCUMENTS**

None available

**PATIENT RESOURCES**

None available

**NGC STATUS**

This NGC summary was completed by ECRI Institute on September 15, 2008. The information was verified by the guideline developer on October 31, 2008.

## **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

## **DISCLAIMER**

### **NGC DISCLAIMER**

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 12/1/2008

